Rheumatology practice marketing: condition pages

A rheumatology practice treats long-lasting conditions such as rheumatoid arthritis, lupus, gout and other autoimmune and inflammatory diseases. A new patient arrives on a referral, after months of joint pain, or after reading online about a diagnosis they were just given. Your website is one of the places they go to learn what the condition is and what treatment means. That makes accuracy the core of the marketing: patients with a chronic disease are a ready audience for claims that a condition can be cured or reversed, and those are the claims a practice has to avoid.

Two related topics have their own guides and are not repeated here. Infusion suites, Medicare Part B cost wording, manufacturer copay coupons, charity assistance and prescription drug terms in Google Ads are in our infusion center marketing guide. Thyroid, bone density and hormone pages are in our endocrinology practice marketing guide. This guide covers what is specific to a rheumatology practice: condition pages, cure and reverse claims, diet and supplement content, and how to write about biologics and biosimilars. For flare pages and diet and supplement claims, see gout clinic marketing.

This is general information, not legal or medical advice. Diagnosis and treatment decisions belong to licensed clinicians, and pharmacy substitution rules for biologics are set state by state. Sources cited were checked on October 30, 2026: the NIAMS health topic pages on rheumatoid arthritis (last reviewed November 2022), lupus (last reviewed October 2022), gout (last reviewed December 2023) and fibromyalgia (last reviewed May 2024), the FDA page Biosimilars Basics for Patients (content current as of August 1, 2024), 42 U.S.C. 262(i), 15 U.S.C. 45 and 52, the FTC Health Products Compliance Guidance (December 2022), 42 U.S.C. 1320a-7b(b), 16 CFR 255.2 and 45 CFR 164.508. Have a health care attorney review your marketing.

Condition pages built on what NIAMS says

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, publishes plain-language pages on the conditions a rheumatology practice treats. Each page shows a last reviewed date. Using them as the factual base for your own condition pages gives patients information they can check against a federal source, and it keeps your pages from drifting into claims you cannot support. A few statements from those pages show the tone:

Rheumatoid arthritis. NIAMS describes it as a chronic (long-lasting) autoimmune disease, and says the goal of treatment is to control the disease so it is in remission or near remission, with no signs or symptoms of the disease. Its treatment page says that once joint damage occurs, it generally cannot be reversed, so early diagnosis and treatment are very important.
Lupus. NIAMS says lupus is a chronic disease and that there is no cure at the present time. It says patients may have periods of illness (flares) and periods of wellness (remission), and that flares are unpredictable.
Gout. NIAMS lists the goals of gout treatment, including reducing the pain from gout flares, and describes diet and lifestyle changes alongside treatment. It tells patients to talk with their doctor before making any changes to their diet or medications.
Fibromyalgia. NIAMS says there is no cure for fibromyalgia, but that doctors and other health care providers can help manage and treat the symptoms.

A condition page that matches this language explains what the condition is, the symptoms that bring patients in, how the diagnosis is made, what the treatment goals are and what a first visit with your practice involves. Link to the NIAMS page for the condition and show the date you last checked it. When NIAMS updates a page, update yours. If a statement on your page goes further than the source, either find a source for it or take it out.

Write the page for the patient who has just been diagnosed. Plain words, short sections and answers to the questions they ask your front desk work better than a list of services. Our healthcare SEO work starts from those questions.

Cure, reverse and drug-free claims

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 makes it unlawful to disseminate a false advertisement to induce the purchase of drugs, devices or services. The FTC Health Products Compliance Guidance explains how the agency applies those laws to health claims. Three of its points matter here:

Claims about health benefits must be supported by “competent and reliable scientific evidence”, and the guidance says that, as a general matter, substantiation of health-related benefits will need to be randomized, controlled human clinical testing.
An ad is responsible for the claims a reasonable reader takes from it, including implied claims. One example in the guidance describes a topical product whose name implies it can cure arthritis, and concludes that the name, before-and-after images and references to joint health likely convey a claim that the product can dramatically improve the symptoms of arthritis.
Another example describes a study of a shake for osteoarthritis symptoms, and says a post hoc analysis of a small subgroup does not provide reliable evidence of a benefit for that group.

Set those points next to the NIAMS pages. NIAMS says joint damage from rheumatoid arthritis generally cannot be reversed, and that lupus and fibromyalgia have no cure. A practice that advertises “reverse your arthritis”, “cure lupus naturally” or “live pain free” is making a claim that contradicts the federal source a patient can read in a minute, and it would need scientific evidence for each reasonable reading of the claim. Wording to keep off your pages and ads:

Cure, reverse, heal or eliminate, applied to a chronic rheumatic disease.
Drug-free, natural or root cause, presented as an alternative to prescribed treatment.
Pain free, flare free or get your life back, presented as a result your patients reach.
Remission as a promise. NIAMS describes remission as a treatment goal, not an outcome every patient reaches.

What you can say is what the practice does and how it works: which conditions your clinicians diagnose and treat, how a new patient visit runs, how treatment plans are reviewed over time, who coordinates care with the patient’s other clinicians, and how the practice handles urgent questions between visits.

Diet, supplements and complementary therapy pages

Patients with arthritis and autoimmune disease ask about diet and supplements, and a page that answers honestly is useful. It is also the page where claims slip. The NIAMS lupus treatment page notes that some people try alternative and complementary therapies such as special diets and nutritional supplements, and warns that some over-the-counter medicines, herbs and supplements can interfere with other medicines. The gout page describes diet and weight changes as part of treatment and tells patients to talk with their doctor before changing diet or medications.

A diet page that follows those sources describes the role of diet as NIAMS does, tells patients to talk with their clinician before changing medications or adding supplements, and makes no claim that a diet or supplement treats, reverses or replaces treatment for a rheumatic disease. If your practice sells supplements, the claim rules and the conflict of interest questions are in our guide to selling supplements in a medical practice. Practices that offer a functional or integrative program alongside rheumatology care can use our functional medicine marketing guide, and regenerative injections for joints are covered in our stem cell clinic advertising guide.

Biologics and biosimilars: use the defined terms

Biosimilar and interchangeable are legal terms with definitions in federal law. Under 42 U.S.C. 262(i)(2), a biosimilar is a biological product that is highly similar to the reference product notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences from the reference product in terms of safety, purity and potency. Under 42 U.S.C. 262(i)(3), an interchangeable product may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.

The FDA page Biosimilars Basics for Patients explains the same terms in plain words. It says a biosimilar is very similar, but not identical, to the original biologic; that a biosimilar and its original biologic have the same treatment risks and benefits; that a biosimilar is not safer or more effective than the original biologic; and that the lower cost of a biosimilar is not a reflection of its effectiveness or safety. It also says pharmacy-level substitution of an interchangeable biosimilar is subject to state law, and that FDA does not regulate whether insurance companies cover or reimburse the cost of biosimilars. For a practice page, that leads to a few rules:

Use biosimilar and interchangeable only as the law and FDA define them. Do not call a biosimilar a generic, a copy or identical.
Do not present a biosimilar as better, safer or weaker than its reference product. FDA says it has the same treatment risks and benefits.
Do not promise savings. FDA does not regulate coverage, and what a patient pays depends on their plan and the setting.
Do not say a patient will be switched, or will not be switched, as a policy. Treatment decisions are made by the prescriber with the patient, and substitution rules are set state by state.
Keep product names out of ads and service pages. That is our own editorial choice, and Google’s prescription drug term rules are covered in our infusion guide linked above.

A short page that explains what a biologic is, what a biosimilar is, and how your practice talks with patients about a change in their medicine, with a link to the FDA page, answers a question patients bring to their visits.

Copay programs and referral sources

Rheumatology patients on biologics ask about manufacturer copay programs. The OIG guidance on those programs, and the wording to use when your site mentions them, is in our infusion center guide linked above. The rule underneath it applies to the whole practice: under 42 U.S.C. 1320a-7b(b), it is a crime to knowingly and willfully offer, pay, solicit or receive remuneration to induce or reward referrals of items or services paid for by a federal health care program. Do not tie a program, a gift or a discount to choosing your practice, and do not offer anything of value to referring clinicians for patients they send. What you can give and receive with referral sources is in our guide to patient and physician referrals. Rules on offers to Medicare patients are in our guide to marketing to Medicare patients.

Referral letters to primary care clinicians can still be useful. Describe the conditions you see, how to send a referral, what records help, and how you report back. If you state a wait time for new patients, it is a factual claim under 15 U.S.C. 45: state only what you measure, and update it when it changes.

Patient stories and reviews

A story about a patient whose disease came under control is persuasive, and it is the kind of story that carries an outcome claim. Under 16 CFR 255.2, an ad that presents one person’s experience on a key point is likely to be read as showing what others will experience, and without substantiation that the result is representative, the ad should clearly disclose the generally expected results. With a disease where NIAMS calls flares unpredictable, a story should describe one person’s experience and say so plainly. A patient’s story or photos held by the practice are protected health information, and 45 CFR 164.508 generally requires written authorization before using them in marketing; see our guide to patient testimonials and before-and-after photos. Condition pages and appointment forms should keep health information away from ad tracking tools; see our guide to tracking pixels on practice websites.

Illustration: two ways to advertise a rheumatology practice

Illustration: [Practice name] runs an ad that reads “Reverse your arthritis without drugs. Our root cause program heals autoimmune disease. Switch to a cheaper biosimilar, the same as a generic.” The landing page shows a patient quote about being pain free in weeks. The ad makes cure and reversal claims that contradict the NIAMS pages, presents a program as a replacement for treatment, misuses the biosimilar term, implies savings no one can promise, and uses an unrepresentative story without a disclosure.

Illustration: [Practice name] runs an ad that reads “Rheumatology care for arthritis, lupus and gout. New patient visits with a rheumatologist, coordinated with your primary care clinician.” The landing page explains how a first visit works, links each condition page to its NIAMS source with the date checked, explains biosimilars in FDA’s words, tells patients to talk with their clinician before changing diet, supplements or medicines, and keeps the appointment form free of ad tracking.

Checklist before a rheumatology campaign goes live

Condition pages match the NIAMS pages they cite, with the date checked shown.
No cure, reverse, heal or drug-free claims for a chronic rheumatic disease, and no remission or pain free promises.
Diet and supplement content tells patients to talk with their clinician first and makes no treatment claim.
Biosimilar and interchangeable used only as defined in 42 U.S.C. 262(i) and explained by FDA, with no generic, identical, better or savings wording.
No product names in ads or service pages, and Google’s drug term rules checked for any that remain.
Copay program wording follows the infusion guide, and nothing of value is tied to choosing the practice or to referrals.
Any stated wait time is measured and current.
Patient stories have written authorization and a disclosure of generally expected results.
Appointment and condition pages keep health information away from ad tracking tools.

Clinics that treat the skin side of psoriasis, or eczema in adults and children, face their own claim, product and photo questions; our guide to psoriasis and eczema clinic marketing covers them.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses. For a rheumatology practice, that means condition and service pages built on dated federal sources, search content written around the questions newly diagnosed patients ask, and appointment and referral forms that keep health information away from tracking tools. We do not decide treatment or whether a claim is substantiated; your clinicians and counsel do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Can a rheumatology practice say it can reverse arthritis?

Avoid it. NIAMS says joint damage from rheumatoid arthritis generally cannot be reversed. Under 15 U.S.C. 45 and 52 and the FTC Health Products Compliance Guidance, a reversal claim needs competent and reliable scientific evidence for each reasonable reading.

Can we mention remission on our website?

Yes, as NIAMS does: as a treatment goal for rheumatoid arthritis. Do not present remission as a result every patient reaches.

Can we call a biosimilar a generic?

No. Under 42 U.S.C. 262(i), a biosimilar is highly similar to its reference product with no clinically meaningful differences, and FDA says it is very similar but not identical to the original biologic. Use the defined terms.

Can we tell patients a biosimilar will save them money?

Not as a promise. FDA says the lower cost of a biosimilar is not a reflection of its safety or effectiveness and that FDA does not regulate insurance coverage. What a patient pays depends on their plan and the setting.

Can our diet page say an anti-inflammatory diet treats lupus or arthritis?

Not without evidence that meets the FTC standard. NIAMS describes diet as part of care for some conditions, warns that some supplements can interfere with medicines, and tells patients to talk with their doctor before changing diet or medications.

Can we share a patient’s remission story?

With written authorization under 45 CFR 164.508, and under 16 CFR 255.2 an unrepresentative result needs a clear disclosure of what patients generally experience.

Rheumatology practice marketing: condition pages, cure claims and biosimilar wording